The global drug delivery devices market is experiencing significant growth, driven by advancements in medical technologies and the increasing demand for more efficient and patient-friendly drug administration systems. With the rise of chronic diseases such as diabetes, cancer, and cardiovascular conditions, the demand for devices like insulin pumps, inhalers, and infusion systems is accelerating. In addition, the shift towards biologics, personalized medicine, and home-based healthcare is pushing the market towards more sophisticated and user-friendly solutions. The integration of digital technologies, such as smart drug delivery systems and mobile health applications, is also transforming the landscape, improving patient adherence and enabling better disease management. Key drivers include the increasing adoption of self-administered therapies, the rise of injectable drugs, and a growing focus on reducing healthcare costs by minimizing hospital visits.
Global Drug Delivery Devices Market is valued at USD 1,748.63 billion in 2023 and is expected to reach USD 3,164.51 billion by 2031, with a growing CAGR of 8.0% during the forecast period 2024 to 2031.
To know more, visit https://www.databridgemarketresearch.com/reports/global-drug-delivery-devices-market
Below are the Top Drug Delivery Devices Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
Johnson & Johnson Services, Inc.
|
Johnson & Johnson Services, Inc. is a leading global healthcare company known for its broad range of medical devices, pharmaceuticals, and consumer health products. In the global drug delivery devices market, J&J is a dominant player, with its comprehensive portfolio of devices used for delivering biologic drugs, insulin, and other medications. The company’s Ethicon and DePuy Synthes brands offer advanced drug delivery systems, including infusion pumps, inhalers, and needle-free injectors, catering to both chronic disease management and acute care. Johnson & Johnson continues to lead the market through innovations in drug delivery systems designed for greater patient comfort, precision, and ease of use.
|
|
Americas, Middle East and Africa, Asia-Pacific, and Europe
|
In August 2023, Janssen Pharmaceutical Companies of Johnson & Johnson Services, Inc. submitted the supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking sanction of DARZALEX in combination with Kyprolis and dexamethasone for relapsed/refractory multiple myeloma. If approved this will increase the product portfolio and also revenue generation of the company.
|
|
2.
|
Novartis AG
|
Novartis AG is a global healthcare company that focuses on the development of pharmaceuticals, eye care, and generics. In the drug delivery devices market, Novartis is recognized for its advanced drug delivery platforms that enhance the administration of medications, especially in the treatment of chronic diseases like cancer and autoimmune disorders. The company’s Aimovig device for migraine and Ilaris auto-injector are examples of Novartis' commitment to improving patient adherence and outcomes by delivering drugs via simple and effective methods. Their focus on digital health and biologics further strengthens their position in the evolving drug delivery sector.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In June 2023, Novartis was signed an agreement to divest ‘front of eye’ ophthalmology assets to Bausch + Lomb, a global eye health company, in a transaction valued up to USD 2.5 billion, including USD 1.75 billion in upfront cash, plus additional milestone payments. The deal includes Xiidra, the first approved prescription treatment for the signs and symptoms of dry eye disease, and investigational medicine SAF312 (libvatrep), in development as a first-in-class therapy for chronic ocular surface pain (COSP), as well as the rights for use of the AcuStream delivery device in dry eye indications and OJL332, a second generation TRPV1 antagonist in pre-clinical development.
|
|
3.
|
F. Hoffmann-La Roche Ltd
|
F. Hoffmann-La Roche Ltd (Roche) is a global leader in the pharmaceutical and diagnostics industries. In the drug delivery devices market, Roche has made significant strides through its innovative solutions for drug administration. The company is particularly known for its injectable biologics, such as Roche's Herceptin and Avastin infusion therapies, which are used in oncology. Roche's efforts to make drug delivery more patient-friendly include the development of smart devices, pre-filled syringes, and auto-injectors. The company's focus on personalized medicine and next-generation drug delivery devices aligns with its commitment to improving patient care and outcomes.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In February 2023, F. Hoffmann-La Roche Ltd expanded collaboration with Janssen to advance personalised healthcare through companion diagnostics. This has helped the company to strengthen its product portfolio.
|
|
4.
|
Bayer AG
|
Bayer AG is a global pharmaceutical and life sciences company specializing in health, agriculture, and materials science. In the drug delivery devices market, Bayer is known for its strong portfolio of injectable devices and oral delivery systems for a variety of therapeutic areas, including oncology, cardiovascular diseases, and diabetes. Bayer has developed implantable drug delivery devices, such as those used in the delivery of contraceptives and chronic disease management. Through ongoing innovation and collaboration, Bayer aims to improve the effectiveness and patient adherence of its drug delivery technologies.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In May 2024, Bayer and its subsidiaries are actively working on the development of 37 products across the Digital Health, In Vitro Diagnostics, and Drug Delivery Devices markets. According to GlobalData’s report, Bayer Medical Device Development, the company provides an overview of its pipeline and offers a detailed analysis of its products currently in development. The devices under development are either in the late stages or early stages of development.
|
|
5.
|
Pfizer Inc.
|
Pfizer Inc. is a leading global biopharmaceutical company that focuses on developing medications and vaccines. In the drug delivery devices market, Pfizer has made significant contributions with devices that deliver vaccines, biologics, and small-molecule therapies. The company has advanced technologies in pre-filled syringes, insulin pens, and auto-injectors for chronic disease management, particularly in diabetes and rheumatoid arthritis. Pfizer's commitment to improving healthcare outcomes extends to the development of digital health solutions that integrate drug delivery with patient monitoring and compliance tracking.
|
|
|
In 2019, Pfizer partnered with Zipline, a leader in drone delivery technology, to expand access to essential medicines in Ghana. This collaboration utilizes drones to deliver vaccines, blood, and other critical health products to remote areas, significantly improving healthcare delivery efficiency.
|
Conclusion
Global drug delivery devices market is poised for continued growth, driven by technological advancements, increasing demand for chronic disease management, and the rise of personalized medicine. The integration of smart technologies and the shift towards home-based healthcare are expected to further fuel market expansion. Despite challenges such as regulatory hurdles and high device costs, ongoing innovations in drug delivery systems and patient-centric solutions will continue to provide significant opportunities. As healthcare needs evolve globally, particularly in emerging markets, the drug delivery devices sector is likely to remain a key area of investment and development, promising both improved treatment outcomes and enhanced patient experiences.
